# Mogrify

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mogrify

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.mogrify.co.uk/
- Total disclosed funding: $47M
- Latest round: Series A (Sep 5, 2023)
- Investors on record: 6

## About

Based in Cambridge, UK, Mogrify Limited also known as Cell Mogrify develops proprietary cell conversion technology that identifies the optimal combination of transcription factors (in vitro) or small molecules (in vivo) to convert any mature cell type into any other mature cell type without going through a pluripotent stem cell or even a progenitor cell-state. The company was founded in 2016 by Jose Polo, Julian Gough, Owen Rackham. In May 2021, Mogrify Limited raised USD 17 million in series A funding led by returning investor Parkwalk Advisors.

Cell Mogrify has developed a proprietary suite of platform technologies that uses a systematic big-data approach to direct cellular reprogramming and the maintenance of cell identity. The platforms are MOGRIFY® and epiMOGRIFY. 

The MOGRIFY® is a proprietary direct cellular reprogramming technology used to identify the key regulatory switches, such as an optimal combination of transcription factors, required to drive cell identity. The platform is used by biopharmaceuticals to enhance their stem-cell forward reprogramming methods or bypass the development pathways altogether causing a direct trans-differentiation between a mature cell type to another mature cell type. 

The epiMOGRIFY is an extension of the MOGRIFY® platform, that is used to identify the optimal culture conditions required to maintain cells and support reprogramming in chemically defined media. It is used by biopharmaceuticals in manufacturing cGMP and improving directed differentiation or transdifferentiation to support the development of scalable off-the-shelf therapies for diseases. 

The company generates revenue by commercializing its platforms as a business model of internal cell therapy development, co-development partnerships, and licensing of novel cell conversions to partners engaged in cell therapy development and regenerative medicine. 

Mogrify Ltd. plans to improve its immuno-oncology and ophthalmology programs, continue the platform development and explore cell reprogramming for novel therapeutic applications.

## Funding rounds

- Series A, Sep 5, 2023, $10M — Astellas Venture Management, Parkwalk Advisors, Trend Investment Group, Ahren Innovation Capital
- Series A, Apr 26, 2021, $17M — Astellas Venture Management, Parkwalk Advisors, 24Haymarket
- Series A, Nov 8, 2019, $16M — University of Bristol Pension and Assurance Scheme, Parkwalk Advisors, 24Haymarket, Ahren Innovation Capital
- Seed, Feb 20, 2019, $3.7M — 24Haymarket, Ahren Innovation Capital

## Investors

- 24Haymarket (https://capitalatlas.ai/funds/24haymarket) — Seed, Series A
- Ahren Innovation Capital (https://capitalatlas.ai/funds/ahren-innovation-capital) — Seed, Series A
- University of Bristol Pension and Assurance Scheme — Series A
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series A
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series A
- Trend Investment Group (https://capitalatlas.ai/funds/trend-investment-group) — Series A